Your browser doesn't support javascript.
loading
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses.
Brown, Jennifer R; Walker, Sarah R; Heppler, Lisa N; Tyekucheva, Svitlana; Nelson, Erik A; Klitgaard, Josephine; Nicolais, Maria; Kroll, Yasmin; Xiang, Michael; Yeh, Jennifer E; Chaudhury, Mousumi; Giaccone, Zachary T; Fernandes, Stacey M; Jacobsen, Eric D; Fisher, David C; Freedman, Arnold S; Davids, Matthew S; Supko, Jeffrey G; Wu, Catherine; Frank, David A.
Afiliação
  • Brown JR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Walker SR; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Heppler LN; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Tyekucheva S; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Nelson EA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Klitgaard J; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Nicolais M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Kroll Y; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Xiang M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Yeh JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Chaudhury M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Giaccone ZT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Fernandes SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Jacobsen ED; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Fisher DC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Freedman AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Supko JG; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Wu C; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Frank DA; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Am J Hematol ; 96(4): E95-E98, 2021 04 01.
Article em En | MEDLINE | ID: mdl-33373063
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimetamina / Leucemia Linfocítica Crônica de Células B / Fator de Transcrição STAT3 / Proteínas de Neoplasias / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimetamina / Leucemia Linfocítica Crônica de Células B / Fator de Transcrição STAT3 / Proteínas de Neoplasias / Antineoplásicos Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article